CEO
Shawn Singh has served as Chief Executive Officer of Vistagen (Nasdaq: VTGN) since 2009 and as a member of the Board of Directors since 2000. Mr. Singh has over 30 years of senior leadership experience in the biopharmaceutical, venture capital and contract research and development sectors. He also served as President of Artemis Neuroscience, acquired by Vistagen, Managing Principal of Cato BioVentures, a healthcare-focused venture capital firm, and Chief Business Officer and General Counsel of Cato Research Ltd (now Allucent), a global CRO and Chief Business Officer of SciClone Pharmaceuticals (formerly Nasdaq: SCLN) before departing to form Cato BioVentures. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster. He holds a B.A. with honors from UC Berkeley and a J.D. from the University of Maryland School of Law.